Cell
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Adcendo Secures $135M for ADC Pipeline Development
Adcendo, ADC pipeline, funding, biotech, cancer treatment, clinical trials
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress
Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance
Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition
Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials
IDEAYA Advances Cancer Pipeline with Biocytogen’s Bispecific ADC, Targeting B7H3/PTK7
IDEAYA, Biocytogen, Bispecific ADC, B7H3/PTK7, Cancer Pipeline, Precision Medicine Oncology
FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks
CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.
Historic Settlement: Lacks Family Reaches Agreement with Thermo Fisher Scientific Over Unjust Enrichment from HeLa Cells
Henrietta Lacks, HeLa cells, Thermo Fisher Scientific, unjust enrichment, racial injustice, medical ethics, consent, biotechnology, settlement.
AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology
AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies
GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager
GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals